No such preventive measure has been discussed to date for anal cancer. No other way of preventing anal cancer is estimated, but its risk can be reduced to some extent. Effective communication with the healthcare team regarding the risk reduction towards cancer is done. The information regarding the administration of HPV vaccination is discussed with the expertise. Tests related to sexually transmitted disease needs to be done regularly. The limitations in contact with more sexual partners need to be maintained. Safe sexual activities need to be followed.
Preventive measures for Anal Cancer
Different factors cause different types of cancer. Researchers continue to study what factors cause anal cancer, such as Preventions of Anal Cancer. There is no proven way to prevent anal cancer completely, but there may be ways to reduce the risk 1. Talk to your health team for more information about your individual’s cancer risk.
- Talk to your doctor about HPV vaccination 2. The HPV vaccine Gardasil is approved by the US Food and Drug Administration (FDA) to prevent anal cancer .
- Anal sex increases the risk of developing HPV and HIV, which may increase the risk of developing anal cancer.
- Regular sexually transmitted disease tests help prevent exposure and help you know what you may have been exposed to in the past. This technique will help you and your doctor know if an Anal cancer test is suitable for you.
- Limit the number of sexual partners. Many partners increase the risk of HPV and HIV infection.
- Use a condom during sexual activity. However, while condoms can be protected from HIV, they cannot be protected entirely from HPV.
- No smoking is also one of the Preventions of Anal Cancer.
- 1.De V, Clifford G, Nascimento M, Madeleine M, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626-1636. doi:10.1002/ijc.24116
- 2.Anderson J, Hoy J, Hillman R, et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr. 2009;52(3):371-381. doi:10.1097/QAI.0b013e3181b7354c